Safety evaluation of immune-cell therapy for malignant tumor in the Cancer Immune-cell Therapy Evaluation Group (CITEG).

Autor: Takimoto R; Seta Clinic Group, Tokyo, Japan; Next Generation Cell and Immunotherapy, Advanced Research Institute for Health Science, Juntendo University, Tokyo, Japan; LSI Sapporo Clinic, Sapporo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan. Electronic address: takimoto@j-immunother.com., Kamigaki T; Seta Clinic Group, Tokyo, Japan; Next Generation Cell and Immunotherapy, Advanced Research Institute for Health Science, Juntendo University, Tokyo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan., Ito H; Seta Clinic Group, Tokyo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan., Saito M; Seta Clinic Group, Tokyo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan., Takizawa K; Seta Clinic Group, Tokyo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan., Soejima K; Seta Clinic Group, Tokyo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan., Yasuda H; Seta Clinic Group, Tokyo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan., Ohgino K; Seta Clinic Group, Tokyo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan., Terai H; Seta Clinic Group, Tokyo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan., Tomita K; Kanazawa Advanced Medical Center, Kanazawa City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan., Miura M; Kanazawa Advanced Medical Center, Kanazawa City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan., Mizukoshi E; Kanazawa Advanced Medical Center, Kanazawa City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan., Miyashita T; Kanazawa Advanced Medical Center, Kanazawa City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan., Nakamoto Y; Kanazawa Advanced Medical Center, Kanazawa City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan., Hayashi K; Kanazawa Advanced Medical Center, Kanazawa City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan., Miwa S; Kanazawa Advanced Medical Center, Kanazawa City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan., Kitahara M; Kanazawa Advanced Medical Center, Kanazawa City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan., Takeuchi A; Kanazawa Advanced Medical Center, Kanazawa City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan., Kimura H; Kanazawa Advanced Medical Center, Kanazawa City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan., Mochizuki T; Kanazawa Advanced Medical Center, Kanazawa City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan., Sugie H; LSI Sapporo Clinic, Sapporo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan., Seino KI; LSI Sapporo Clinic, Sapporo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan., Yamada T; LSI Sapporo Clinic, Sapporo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan., Takeuchi S; LSI Sapporo Clinic, Sapporo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan., Makita K; Kitaosaka Medical Clinic, Suita City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan., Naitoh K; Fukuoka Medical Clinic, Fukuoka City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan., Yasumoto K; Fukuoka Medical Clinic, Fukuoka City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan., Yoshida Y; Fukuoka Medical Clinic, Fukuoka City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan., Inoue H; Fukuoka Medical Clinic, Fukuoka City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan., Kotake K; Masuko Memorial Hospital, Nagoya City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan., Ohshima K; Heisei-Hidaka Clinic, Gunma, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan., Noda SE; Heisei-Hidaka Clinic, Gunma, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan., Okamoto M; Heisei-Hidaka Clinic, Gunma, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan., Yoshimoto Y; Heisei-Hidaka Clinic, Gunma, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan., Okada S; Seta Clinic Group, Tokyo, Japan; Next Generation Cell and Immunotherapy, Advanced Research Institute for Health Science, Juntendo University, Tokyo, Japan., Ibe H; Seta Clinic Group, Tokyo, Japan; Next Generation Cell and Immunotherapy, Advanced Research Institute for Health Science, Juntendo University, Tokyo, Japan., Oguma E; Seta Clinic Group, Tokyo, Japan; Next Generation Cell and Immunotherapy, Advanced Research Institute for Health Science, Juntendo University, Tokyo, Japan., Goto S; Seta Clinic Group, Tokyo, Japan; Next Generation Cell and Immunotherapy, Advanced Research Institute for Health Science, Juntendo University, Tokyo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan.

Publikováno v: Cytotherapy [Cytotherapy] 2023 Nov; Vol. 25 (11), pp. 1229-1235. Date of Electronic Publication: 2023 Jul 22.

Tumor-Specificity, Neurotoxicity, and Possible Involvement of the Nuclear Receptor Response Pathway of 4,6,8-Trimethyl Azulene Amide Derivatives.

Autor: Naitoh K; Faculty of Science, Josai University, Saitama 250-0295, Japan., Orihara Y; Faculty of Science, Josai University, Saitama 250-0295, Japan., Sakagami H; Research Institute of Odontology, Meikai University, Sakado, Saitama 350-0283, Japan., Miura T; Faculty of Science, Josai University, Saitama 250-0295, Japan., Satoh K; Division of Pharmacology, Department of Diagnostics and Therapeutics Sciences, Meikai University School of Dentistry, Saitama 350-0283, Japan., Amano S; Research Institute of Odontology, Meikai University, Sakado, Saitama 350-0283, Japan., Bandow K; Division of Biochemistry, Department of Oral Biology and Tissue Engineering, Meikai University School of Dentistry, Saitama 350-0283, Japan., Iijima Y; Department of Oral and Maxillofacial Surgery, Saitama Medical Center, Saitama Medical University, Saitama 350-0283, Japan., Kurosaki K; Department of Medical Molecular Informatics, Meiji Pharmaceutical University, Tokyo 204-8588, Japan., Uesawa Y; Department of Medical Molecular Informatics, Meiji Pharmaceutical University, Tokyo 204-8588, Japan., Hashimoto M; Faculty of Science, Josai University, Saitama 250-0295, Japan., Wakabayashi H; Faculty of Science, Josai University, Saitama 250-0295, Japan.

Publikováno v: International journal of molecular sciences [Int J Mol Sci] 2022 Feb 26; Vol. 23 (5). Date of Electronic Publication: 2022 Feb 26.

[Double Patch Closure for Ruptured Sinus of Valsalva Aneurysm:Report of a Case].

Autor: Sato M; Department of Cardiovascular Surgery, Saga-ken Medical Center Koseikan, Saga, Japan., Kawasaki H, Naitoh K, Uchino M

Publikováno v: Kyobu geka. The Japanese journal of thoracic surgery [Kyobu Geka] 2021 May; Vol. 74 (5), pp. 392-395.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Development and validation of an instrument to evaluate the perspective of using the electronic health record in a hospital setting.

Autor: Rhayha, Radouane^1,2 (AUTHOR) radouane.rhayha@usmba.ac.ma, Alaoui Ismaili, Abderrahman¹ (AUTHOR)

Publikováno v: BMC Medical Informatics & Decision Making. 10/8/2024, Vol. 24 Issue 1, p1-13. 13p.